Login to View
StrategyR is a trade mark of Global Industry Analysts, Inc. USA
A trade mark of Global Industry Analysts, Inc.


Combination Antibody Therapy

A Global Strategic Business Report

MCP11165


    0
RESEARCH TRANSCRIPTS
First Distinguished Bristol-Myers Squibb Lecture in Immunology
LOW OKAY GOOD GREAT
0

MY SILO

DESCRIPTION:

Lecture delivered on June 17, 2010. This is the first Distinguished Lecture in Immunology supported by Bristol-Myers Squibb. UC Irvine Institute For Immunology presents Michael D. Cahalan, Ph.D., Professor and Chair Department of Physiology and Biophysics Institute for Immunology University of California, Irvine.

TRANSCRIPT:

BMY Stock | Bristol Myers Squibb Co Q2 2020 Earnings Conference Call
LOW OKAY GOOD GREAT
0

MY SILO

DESCRIPTION:

Bristol-Myers Squibb Co (BMY) Q2 2020 Earnings Report https://news.alphastreet.com/earnings-bristol-myers-squibb-company-nyse-bmy-reports-q2-2020-results/

TRANSCRIPT:

We have an accelerated opportunity to renew our portfolio, says Bristol Myers Squibb CEO
LOW OKAY GOOD GREAT
0

MY SILO

DESCRIPTION:

Dr. Giovanni Caforio, Bristol Myers Squibb CEO, joins the 'Halftime Report' to discuss his company's collaboration with Century Therapeutics. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NGeIvi  » Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision » Subscribe to CNBC: https://cnb.cx/SubscribeCNBC Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide. The News with Shepard Smith is CNBC’s daily news podcast providing deep, non-partisan coverage and perspective on the day’s most important stories. Available to listen by 8:30pm ET / 5:30pm PT daily beginning September 30: https://www.cnbc.com/2020/09/29/the-news-with-shepard-smith-podcast.html?__source=youtube%7Cshepsmith%7Cpodcast    Connect with CNBC News Online Get the latest news: http://www.cnbc.com/ Follow CNBC on LinkedIn: https://cnb.cx/LinkedInCNBC Follow CNBC News on Facebook: https://cnb.cx/LikeCNBC Follow CNBC News on Twitter: https://cnb.cx/FollowCNBC Follow CNBC News on Instagram: https://cnb.cx/InstagramCNBC https://www.cnbc.com/select/best-credit-cards/  #CNBC #CNBCTV

TRANSCRIPT:

THALIA MINGO | Global Lead Bristol Myers Squibb Network of women ( B_Now)
LOW OKAY GOOD GREAT
0

MY SILO

DESCRIPTION:

This special meeting on Women Inspiring a Peaceful & Sustainable Future was hosted by CSPOC at United Nations of Geneva. The event was directed and curated by Kristin Engvig and produced by GCF & WIN. GCF and WIN have worked together since 2019 and their women pioneering global change initiative includes the 16th May 2022 and the 11th May 2023 meeting in Geneva. It will conclude in New York in 2024

TRANSCRIPT:

2016 WMIF | Fireside Chat: Giovanni Caforio, MD, CEO, Bristol-Myers Squibb
LOW OKAY GOOD GREAT
0

MY SILO

DESCRIPTION:

Introduction by: Thomas Lynch, MD, CEO, Mass General Physician's Organization Moderator: Meg Tirrell, Biotech and Pharma Reporter, CNBC Giovanni Caforio, MD, CEO, Bristol-Myers Squibb

TRANSCRIPT:

AWS re:Inforce 2022 - Bristol Myers Squibb: Automate multi-account, FinOps, security & DevOps
LOW OKAY GOOD GREAT
0

MY SILO

DESCRIPTION:

As organizations move more workloads to the cloud, they have a growing need for security and governance. Cloud teams are asked to use new AWS Regions and services while meeting the compliance needs of the business. In this session, Bristol Myers Squibb, a leading global life sciences company, dives deep into how they have implemented a fully automated self-service platform. Learn how they enabled self-service for all business users, centrally managed network and data resources, and automated governance. Also learn how they used AWS Control Tower and AWS Service Catalog to support controls and deliver best practice kits in their cloud environment. (GRC-202) Learn more about AWS re:Inforce at https://bit.ly/3baitIT. Subscribe: More AWS videos http://bit.ly/2O3zS75 More AWS events videos http://bit.ly/316g9t4 ABOUT AWS Amazon Web Services (AWS) hosts events, both online and in-person, bringing the cloud computing community together to connect, collaborate, and learn from AWS experts. AWS is the world’s most comprehensive and broadly adopted cloud platform, offering over 200 fully featured services from data centers globally. Millions of customers—including the fastest-growing startups, largest enterprises, and leading government agencies—are using AWS to lower costs, become more agile, and innovate faster. #reInforce2022 #CloudSecurity #AWS #AmazonWebServices #CloudComputing

TRANSCRIPT:

Krishna Cheriath, Bristol Myers Squibb | MITCDOIQ 2020
LOW OKAY GOOD GREAT
0

MY SILO

DESCRIPTION:

Krishna Cheriath sits down with Dave Vellante for a digital CUBE Conversation as part of the MIT CDOIQ 2020 Symposium

TRANSCRIPT:

Intellectual Property Protection for Life Science AI Assets with Bristol Myers Squibb
LOW OKAY GOOD GREAT
0

MY SILO

DESCRIPTION:

E. Jay Wilusz, Senior Corporate Counsel, Bristol Myers Squibb AI continues to increase the speed and efficiency of the entire bandwidth of pharmaceutical interests. Those interests include drug discovery, clinical data processing, and digital interfaces between patients and providers to improve treatment outcomes. How should nascent and established companies protect their AI and ML intellectual property assets? I will describe how to balance patent protection or secrecy agreements against the need to publicize technology improvements, technology lifespan, and the ability to monitor for infringement and defend IP rights.

TRANSCRIPT:

AWS re:Invent 2019: Data lakes reimagined: Efficiency & innovation at Bristol-Myers Squibb (LFS204)
LOW OKAY GOOD GREAT
0

MY SILO

DESCRIPTION:

The increasing amount of data available to pharmaceutical companies creates pressure on R&D teams to orchestrate and analyze that data and generate insights that will help patients prevail over serious diseases. In this session, learn how Bristol-Myers Squibb used AWS services to create a platform-based approach for ingesting, preparing, curating, and persisting business-critical data for digital integration, analytics, and insights generation. Hear how this approach has improved the company’s efficiency, enhanced cost savings, and decreased the time-to-service for its data customers. Additionally, gain an understanding of the lessons learned from this process, and learn best practices for other organizations.

TRANSCRIPT:

Rev 1 "Keynote: Deciphering Modern Cancer Therapy with Bioinformatics" - Bristol Myers Squibb
LOW OKAY GOOD GREAT
0

MY SILO

DESCRIPTION:

TRANSCRIPT:

Immutep (ASX:IMM, NASDAQ:IMMP) LAG-3 validated in Bristol Myers Squibb trial
LOW OKAY GOOD GREAT
0

MY SILO

DESCRIPTION:

29 Mar 2021 - Immutep Limited (ASX:IMM, NASDAQ:IMMP) CEO and Executive Director Marc Voigt talks about the Bristol Myers Squibb trial evaluating Anti-LAG-3 Antibody Relatlimab and Opdivo (nivolumab) in patients with previously untreated metastatic or unresectable melanoma, meeting its primary endpoint of progression-free survival and what it means for Immutep.

TRANSCRIPT:

Benchling Virtual Launch Event – Fireside Chat with Dr. Kristen Hege of Bristol Myers Squibb
LOW OKAY GOOD GREAT
0

MY SILO

DESCRIPTION:

Kristen Hege, M.D., is Senior Vice President, Early Clinical Development, Hematology/Oncology & Cell Therapy, at Bristol Myers Squibb. At Benchling’s virtual launch event, Dr. Hege discussed her 30+ year hybrid academic/industry career in cell therapy, from the emergence of the field during the AIDS crisis in the ‘90s, to incredible outcomes in patients with blood cancers in the 2010s, and the approval of the first BCMA CAR T product in 2021. —————————— Benchling is the pioneer of the R&D Cloud, software that powers the biotechnology industry. More than 200,000 scientists at over 600 companies and 7,000 research institutions globally have adopted Benchling’s R&D Cloud to make breakthrough discoveries and bring the next generation of medicines, food, and materials to market faster than ever before. The R&D Cloud helps these organizations modernize their scientific processes and accelerate collaboration so they can convert the complexity of biology into world-changing results. To learn more, visit https://www.benchling.com/

TRANSCRIPT:

UGM2020 / 24. iRODS at Bristol Myers Squibb: Leveraging iRODS for scientific applications in AWS
LOW OKAY GOOD GREAT
0

MY SILO

DESCRIPTION:

Mohammad Shaikh, Bristol Myers Squibb Oleg Moiseyenko, Bristol Myers Squibb June 11, 2020 - Virtual https://irods.org/ugm2020

TRANSCRIPT:

Shalu Chadha, Accenture & Kathleen Natriello, Bristol-Myers Squibb | AWS Executive Summit 2018
LOW OKAY GOOD GREAT
0

MY SILO

DESCRIPTION:

Shall Chadha, Sr. Technology Services Lead, Accenture & Kathleen Netriello, Vice President and Head of IT Digital Design, Bristol Myers-Squibb sit down with Rebecca Knight t the AWS Executive Summit at AWS re:Invent. #AWS #theCUBE #AWSSummit https://siliconangle.com/2018/12/27/cloud-ai-services-dose-big-pharma-with-overdue-speed-agility-reinvent/ Cloud AI services dose big pharma with overdue speed, agility What industry could stand to pick up its pace more than pharmaceutical research? Look at the price of drugs in the U.S. It can take over 10 years and billions of dollars to develop one pill. Providing insight and historical context, modern machine-learning technologies could make pharma a more efficient industry. Bristol-Myers Squibb Co. is adopting cloud technologies to speed up research into immuno-oncology therapies. These treatments boost the immune system in order to fight cancer. “Our highest priority was our scientists’ productivity,” said Kathleen Natriello (pictured, right), vice president of corporate information technology at Bristol-Myers Squibb. BMS has teamed up with Amazon Web Services Inc. and Accenture LLP to develop solutions for its scientists and business units. Genomics research requires huge volumes of data. With machine learning and artificial intelligence services from AWS, BMS scientists have drastically reduced the time it takes to process them. Natriello and Shalu Chadha (pictured, left), technology lead, products North East North America, at Accenture, spoke with Rebecca Knight (@knightrm), host of theCUBE, SiliconANGLE Media’s mobile livestreaming studio, during the AWS Executive Summit in Las Vegas. They discussed how the three-way partnership is injecting speed and agility into typically glacier-paced pharma processes. (* Disclosure below.) It’s about time for agility in pharma BMS has implemented several AWS cloud services that enable scientists to use AI for computational approaches and simulations. They slash the time and cost required to complete an experiment, according to Natriello. “They no longer have to use actual physical material or patients or investigators. They can do it all through simulation and modelling,” she said. It uses AI-powered robotics process automation across legal and compliance, and is now starting to use them in clinical trials. It is trying to become “quicker with how the patients are going to see both responses to adverse events, as well as how do you accelerate the clinical trial process,” Chadha said. Scientists are the biggest advocates for the introduction of new tech, according to Natriello. “They are doing things with machine learning and artificial intelligence with these simulations … in a few hours that used to take them weeks and months,” she stated. Business functions are enthusiastically on-board as well. “Very often, the business functions are the ones that introduce the new technologies, because they’re really interested in it,” Natriello concluded. Watch the complete video interview below, and be sure to check out more of SiliconANGLE’s and theCUBE’s coverage of the AWS Executive Summit. (* Disclosure: TheCUBE is a paid media partner for the AWS Executive Summit event. Neither Accenture LLP, the event sponsor, nor other sponsors have editorial control over content on theCUBE or SiliconANGLE.)

TRANSCRIPT:

Day 2 - Track 1 - Bristol Myers Squibb Commitment to Addressing Health Disparities and Diversity
LOW OKAY GOOD GREAT
0

MY SILO

DESCRIPTION:

Sign up for our next summit for free here: https://bit.ly/PTFSummit Bristol Myers Squibb recognizes and celebrates the diverse experiences and views of their workforce. They encourage every employee to bring their authentic selves to work so they can fully engage in a meaningful way and drive the company's mission to help patients prevail over serious diseases. Bristol Myers Squibb's PRIDE Alliance is a vital part of that effort, helping to ensure a diverse and inclusive culture that empowers LGBTQ+ inclusion, awareness, and engagement. For this roundtable discussion, we are joined by several BMS leaders to share their career journeys and take a deep dive into BMS's Heath Equity approach and work including how prior partnerships with HIV and LGBTQ+ communities became the playbook for the current initiatives. PowerToFly's Meg Alexander will moderate. Sign up for our next summit for free here: https://bit.ly/PTFSummit

TRANSCRIPT:

ACP Presents: Careers at Bristol Myers Squibb
LOW OKAY GOOD GREAT
0

MY SILO

DESCRIPTION:

On April 21st, Bristol Myers Squibb joined ACP in hosting a "Careers At BMS" webinar for interested veteran and military spouse Protégés. The event featured a panel of BMS employees who spoke about company culture, job opportunities, and their own personal transitions from the military to Corporate America. The event closed with a Q&A session from the 85-person virtual audience. Many thanks to Marty, Pat, Ricardo, Kristen and Marissa for a terrific event!

TRANSCRIPT:

Career Zoo October 2016 Main Stage: Bristol-Myers Squibb Keynote
LOW OKAY GOOD GREAT
0

MY SILO

DESCRIPTION:

Compere Jonathan McCrea speaks with MIke Furlong, Executive DIrector, Cruiserath Biologics, BMS, Mairead Looby, Director, Manufacturing Science and Technology, BMS, Donagh Walls, Associate Director, QC Site Operations, BMS, and Lisa Cahill, HR Manager, BMS.

TRANSCRIPT:

MDS SATELLITE SYMPOSIUM (English) - Bristol Myers Squibb Company
LOW OKAY GOOD GREAT
0

MY SILO

DESCRIPTION:

Latin-American GLAM and MDSF Symposium 2021 MDS SATELLITE SYMPOSIUM (English) Bristol Myers Squibb Company Low Risk MDS, new therapeutic strategies Chairman: Alicia Enrico (ARG) Speaker: Guillermo García Manero (USA)

TRANSCRIPT:

    0